Skip to content
10-Q

Quarterly Report

Xilio Therapeutics, Inc. XLO

0001193125-26-218200

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Capex Q1 2026 · Mar 31, 2026 $556K
Capex Q1 2026 · Mar 31, 2025 $22K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$22.34M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $28.98M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $150.33M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $137.53M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $89.07M
Stockholders Equity Q1 2026 · Mar 31, 2026 $72.55M
Stockholders Equity Q1 2026 · Dec 31, 2025 $35.27M
Stockholders Equity Q1 2026 · Mar 31, 2025 $10.7M
Stockholders Equity Q1 2026 · Dec 31, 2024 $17.6M
Current Liabilities Q1 2026 · Mar 31, 2026 $42.96M
Current Liabilities Q1 2026 · Dec 31, 2025 $56.27M
Total Liabilities Q1 2026 · Mar 31, 2026 $90.94M
Total Liabilities Q1 2026 · Dec 31, 2025 $119.41M
Current Assets Q1 2026 · Mar 31, 2026 $154.21M
Current Assets Q1 2026 · Dec 31, 2025 $145.03M
Total Assets Q1 2026 · Mar 31, 2026 $163.49M
Total Assets Q1 2026 · Dec 31, 2025 $154.69M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.58
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$2.49
Eps Basic Q1 2026 · Mar 31, 2026 −$0.58
Eps Basic restated Q1 2026 · Mar 31, 2025 −$2.49
Sga Expense Q1 2026 · Mar 31, 2026 $6.93M
Sga Expense Q1 2026 · Mar 31, 2025 $8.52M
Rd Expense Q1 2026 · Mar 31, 2026 $19.83M
Rd Expense Q1 2026 · Mar 31, 2025 $8.27M
Net Income Q1 2026 · Mar 31, 2026 −$9.53M
Net Income Q1 2026 · Mar 31, 2025 −$13.27M
Operating Income Q1 2026 · Mar 31, 2026 −$14.11M
Operating Income Q1 2026 · Mar 31, 2025 −$13.85M
Revenue Q1 2026 · Mar 31, 2026 $12.65M
Revenue Q1 2026 · Mar 31, 2025 $2.93M